Milestone Histories and Paradigmatic Genetic Discoveries of Chronic Myeloid Leukemia (CML) by Wu, Zhan He
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
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Paradigmatic Genetic Discoveries 
of Chronic Myeloid Leukemia 
(CML)
Zhan He Wu
Abstract
Chronic myeloid leukemia (CML) is classified as a hematological malignant rare 
disease by National Organization for Rare Disease (NORD, USA) based on the esti-
mated incidence of 1–2 cases/100,000 per year internationally. CML occurs in all ages 
but commonly seen in the 45–55 years group. Males are slightly more affected than 
females. CML is one of the oldest known diseases with new faces and one of the fastest 
developing diseases with many extraordinary discoveries in human history of con-
quering the disease. CML possesses at least Nine First findings in leukemia and cancer 
research and even in human medical histories: the First named as leukemia in 1845, the 
First of a live case of CML patient diagnosed in 1846, the First used of arsenic in CML 
treatment in 1865, the First defined as a myeloproliferative disorder in 1951, the First 
finding of Philadelphia chromosome (Ph chromosome) in 1960, the First finding of 
chromosome 9 and 22 translocations in 1973, the First identified as a clonal hemato-
logical malignancy derived from the stage of pluripotent bone hematopoietic stem cells 
in 1977, the First finding of the chromosomal fusion gene-BCR-ABL as an oncogene in 
1984, and the First designed target therapy of use of tyrosine kinase inhibitor (TKI) 
in 1998. The footprints of the studies on CML established the milestone histories. 
Remarkable and fascinating genetic discoveries were made of the mysteries of human 
diseases, the multiway translocation of Ph chromosome, and the latest issues. The 
association of the combination of chronic myeloid leukemia and chronic lymphocytic 
leukemia will be reviewed in this chapter with the aim of increasing the understanding 
of CML further from laboratory bench to clinical bedside.
Keywords: rare hematological malignancy, chronic myeloid leukemia,  
genetic variations, Philadelphia chromosome, BCR-ABL gene
1. Introduction
Myeloproliferative neoplasm (MPN) is a rare type of hematological malignancy 
featured by the excessive proliferation of single or multilineages of hematopoietic 
cells in the bone marrow affecting fewer than six in 100,000 people. MPN mainly 
includes polycythemia vera (PV), essential thrombocythemia (ET), primary 
myelofibrosis (MF), and chronic myeloid leukemia (CML) classified by World 
Health Organization (WHO) [1].
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Among these types of MPN, CML, with several synonyms of chronic myeloge-
nous leukemia, chronic granulocytic leukemia, is the most common type of myelo-
proliferative disorder characterized by increased proliferation of the granulocytic 
cell line without the loss of their capacity to differentiate.
CML consists of about 20% of all leukemias affecting individuals of all ages 
including children and infants with chronic, accelerated, and blast crisis phases to 
acute leukemia resulting in life-threatening situation [2].
CML presents as easy bleeding, splenomegaly, feeling run down or tired, fever, 
loss of weight without trying, loss of appetite, pain or fullness below the ribs on the 
left side, pale skin, and excessive sweating during sleep (night sweats) [3].
CML has a very exciting history and extraordinary findings in which it has paved the 
way toward clinical diagnosis and treatment. It was predicted by John Gordon in 2003 
that the fascinating CML could be becoming even more fascinating from now on [4].
2. Milestone histories and remarkable genetic discoveries of CML
The remarkable genetic discoveries have been translating into clinical diagnosis, 
effective, and specific therapies from the following so many FIRST findings.
2.1 The first named as a leukemia
CML was first named as leukemia in the nineteenth century, when it was 
described and recognized in 1845 from descriptions of the clinical presentations 
and symptoms by Bennett, Virchow, and Craigie [5–7].
Cells from blood or bone marrow morphology from patient with CML show 
at every stage differential cells due to partial blockage, unlike the maturation and 
differentiation of acute leukemia, which are blocked completely in the early cell dif-
ferential stage. The chronic term of CML refers to maturation and differentiation, 
unlike other diseases by period of disease duration.
2.2 The first of a live case of CML patient diagnosed
The first live patient with CML was diagnosed in 1846 by Dr. Henry Fuller, 
a physician at St George’s Hospital in London with the identification of a large 
proportion of abnormal, granular colorless globules under microscope [8].
2.3 The first used of arsenic in CML treatment
Fowler’s solution, the compounded a potassium bicarbonate-based solution of 
arsenic trioxide (As2O3) invented by Thomas Fowler named as Fowler’s solution in 
1786, was first tried in CML among all leukemias in 1865 to reduce the over prolif-
erative white cell numbers [9].
Very excitingly, the arsenic has been used to cure acute promyelocytic leukemia 
(APL) which it made the worst and incurable type of leukemia; APL became the 
best therapeutical curable type among all types of leukemias achieved by several 
Chinese medical researchers [10].
2.4 The first defined as a myeloproliferative disorder
CML was first introduced as a myeloproliferative disorder based on the evidence 
accumulated of multiple abnormalities involved in erythroblasts, granulocytes, 
megakaryocytes, but no fibroblasts in bone marrow by Dameshe [11].
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2.5 The first finding of Ph chromosome in leukemia
Ph chromosome was first reported in 1960 by Nowell and Hungerford [12]. 
Originally such a finding was described as deletion of the long arm of chromosome 
22, although it was thought to be chromosome 21 [13] and was even thought to 
be the chromosome Y due to limitation of low chromosomal resolution from the 
cytogenetic technique at that time [14, 15]. The smart conclusion made from this 
was the suggestion that such chromosome change could be associated with CML.
Since then the detection of Ph chromosome by the application of the cytogenetic 
(Karyotyping) and the molecular cytogenetic techniques, fluorescence in-situ 
hybridization (FISH) has become a very useful and practical approach in the diag-
nosis and monitor of CML. Cytogenetic karyotype analysis is a specific, accurate, 
low cost, fast technology in CML diagnosis, and disease monitoring in the detection 
of both classical and variant Ph translocation.
2.6 The first identified as a translocation of chromosomes 9 and 22 in leukemia
In 1973, Ph chromosome or Ph translocation was identified as balanced translo-
cated chromosomes 9 and 22, t[q34;q11], by Rowley [16]. Such milestone finding 
identified and classified the Ph chromosome was not the shortening of chromosome 
22 as found by Nowell and Hungerford, which it pointed out the direction and 
narrowed down to the discovery of CML causing gene from the initial finding of the 
association between Ph chromosome and CML.
2.7 The first finding of BCR-ABL gene in leukemia
Breakpoint cluster region-Abelson leukemia (BCR-ABL) virus was the first find-
ing from CML in leukemia and oncology. BCR-ABL is a fusion oncogene, resulting 
in CML from the translocation at the breakpoints of the long arm of chromosome 9 
and the long arm of chromosome 22 and in humans [17] and mice [18–20].
Studies found that BCR-ABL fusion gene has several types of isoform protein 
products from the different breakpoints of translocated. The common types are 
the fusion protein products (p210, p190, and p230), resulting in the enhance-
ment of tyrosine kinase activity in CML and other types of hematological 
malignancies in the similar mechanism [21]. The concept from such findings 
obtained provided the valuable theory for the development of the target-specific 
therapy afterward.
The detection of BCR-ABL gene using PCR technique commonly has become a 
valuable/effective and sensitive approach in the diagnosis and disease monitoring of 
CML, which it does not require cell culture.
2.8  The first clinical therapy by using tyrosine kinase inhibitor (TKI) in 
leukemia
CML has a long developmental history in the trial of treatment in the past, 
including the first trial by using arsenic (Fowler’s solution), x-irradiation, nitrogen 
mustard, busulfan, hydroxyurea, interferon-α, and stem cell transplantation. 
The tyrosine kinase inhibitor (TKI) is considered as the first and a successfully 
designed first-generation target therapy in cancer therapies clinically. This therapy 
was designed on the base of blocking and deregulating the activity of BCR-ABL 
fusing gene 1998 [22]. The second-generation TKI started to be used for reducing 
the resistance was developed in 2004. Such specific therapy significantly prolonged 
lifespan for patients with CML.
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2.9 The first described as a clonal hematological disease in leukemia
Cells from bone marrow or peripheral blood of a patient with CML show exces-
sive proliferation from one or multiple lineages and different maturation stages due 
to the partial blocking of differentiation.
CML was first identified as a clonal hematological malignancy from pluripotent 
bone marrow stem cells [23, 24]. Such finding increased our understanding of the 
stages of disease mechanism and helps in the diagnosis, differential diagnosis, and 
treatment.
3. Variant complex and multiway translocations of Ph chromosome
3.1 Variant complex translocation of Ph chromosome
Cytogenetically, CML is characterized by the Ph chromosome formed by the 
fusion gene of the reciprocal translocation t(9:22)(q34;q11), resulting in the chime-
ric gene breakpoint cluster region (BCR)-Abelson leukemia (ABL).
Studies demonstrated that approximately 90–95% CML patients have Ph 
chromosome from the classical reciprocal translocations. However, about 5–10% 
CML cases have variant types of the Ph chromosome. The variant Ph chromosome 
translocations are involving chromosomes other than 9 and 22 or multiple chromo-
somes involved in CML cases [25]. Some studies also suggested that the classical 
and variant Ph chromosome translocations in CML patient have showed different 
sensitivities to treatment [26].
Mysorekar et al. reported five male CML cases with variant Ph chromosome 
translocations. Two cases were two-way translocations, t(16;22), t(15;22), and three 
cases were three-way translocations, t(1;9;22), t(9;9;22), t(9;14;22), and all cases 
studied were with BCR-ABL fusion gene, but responded well to the tyrosine kinase 
inhibitors, imatinib treatment in their studied cases [27].
3.2 Three-way translocation of Ph chromosome
Three-way translocation involves three chromosomes including the Ph chromo-
some. Such complex translocation was found not only in adult but also in childhood.
Lee reported a 22-year-old male CML case with a three-way translocation 
involving in chromosomes 9, 22, and 11 at the breakpoints of q34;q11.2;q24 detected 
by using cytogenetic-G banding and FISH techniques, and this patient responded 
well to TKI treatment imatinib [28].
Asif groups reported male CML case with a three-way translocation involving 
chromosomes 9, 11, and 22 at the breakpoints of q34;p15;q11 in separate studies [29].
Allen-Proctor group reported a male CML case with a three-way translocation 
involved in chromosomes 9, 22, and 17 at the breakpoints of q34;q11.2;q12 detected 
by using cytogenetic analysis of G banding and FISH [30].
Most three-way translocations reported were primary abnormalities. Achkar 
et al. reported a male CML case with a three-way translocation involved in chromo-
somes 9, 10, and 22 at the breakpoints of q34;p11.2;q11.2 and also loss of Y chromo-
some as a secondary abnormality after the classical Ph translocation of t(9;22) 
followed by chemotherapy [31].
CML is very low in childhood and infant. Three-way translocation of Ph chromo-
some in infant is extremely rare. An 10-month-old boy infant with three-way Ph trans-
locations involved in chromosomes 9, 22, and 14 at the breakpoints of q34;q11.2;q32 by 
using GTG banding and FISH techniques and confirmed the presence of BCR-ABL by 
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RT-PCR was reported as the first case with the accelerated phase and received favor-
able response with hydroxyl urea and the TKI (dasatinib) [32].
3.3 Four-way translocation of Ph chromosome
Four-way translocation involves four chromosomes including the Ph chromo-
some. Asif et al. reported a four-way translocation involved in chromosomes 4, 
9, 19, and 22. They have reviewed and analyzed 59 cases of CML with four-way 
translocations reported from the literatures previously. Their analysis showed that 
56% of four-way translocation was male, 39% was female, 2% was missing chromo-
some Y (-Y), and 3% was unidentifiable of sex [33].
Achkar group reported a four-way translocation involving chromosomes 9, 11, 
20, and 22 [34]. The same group reported another case with four-way transloca-
tions involved in chromosomes 9, 11, 20, and 22. Also, BCR-ABL fusion gene 
was detected by reverse transcription polymerase chain reaction (RT-PCR). That 
patient also showed additional chromosome abnormalities involving translocations 
of chromosomes 7 and 8. Patient showed poor response to imatinib and died for 
unknown reason [35].
3.4 Five-way translocation of Ph chromosome
Five-way translocation is involved in five chromosomes including the Ph 
chromosome. A novel five-way translocation involved in chromosomes 7, 11, 9, 22, 
and 9 detected by G-banding technique and confirmed by spectral karyotyping 
(SKY); BCR-ABL gene was detected by fluorescence in-situ hybridization (FISH), 
which was reported by Yokota group in 2012, and patients showed good respond to 
imatinib treatment and also reviewed another nine cases of five-way translocations 
compared with their case reported in that article [36].
Another five-way translocations of 29-year-old male CML case involved in 
chromosomes 9, 11, 13, 19, and 22 by G-banding technique confirmed by SKY, and 
BCR-ABL gene fusion by Vaidya group reported a five-way translocation involved 
in chromosomes 9, 11, 13, 19, and 22, and that case responded well to imatinib treat-
ment [37].
The mechanism of variant complex translocation is still unknown. The spatial 
arrangement is involved in chromosomes because they require the physical interac-
tion of the translocation partners and the association of genomic instability could 
be associated with multiway translocation.
3.5  The application of next-generation sequencing (NGS) and the detection of 
other genes associated with CML
Currently, cytogenetics, FISH, and qRT-PCR have been using as the routine 
techniques in the applications of CML diagnosis. However, each of them has his/
her limitation in the application. NGS technique is a powerful technique with high 
throughput. Lyu group identified a novel BCR-ABL1 fusion gene with breakpoints 
in the BCR intron 14 and the ABL1 intron 2 (with an e14a3) by using NGS [38].
Shokeen group studied CML cases by using NGS and found some variants and 
potential prognostic and susceptibility markers, which helped them in the predic-
tion of TKI therapy [39].
Fu group studied BCR-ABL fusion gene variants on CML by using next-
generation sequencing (NGS), and they found an e13a2-like novel form of BCR-
ABL fusion, while it was negative with qRT-PCR-based test, which helped them in 
diagnosis and therapy. Their results suggested that NGS is a powerful technique 
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to detect BCR-ABL fusion variants, which they could be missed by other routine 
techniques. In addition, other mutated genes SETBP1, PAX5, and TP53 were also 
detected [40]. Such findings of additional mutated genes involved in CML by NGS 
may increase the understanding in leukemogenesis and help in treatment for cases 
with CML with TKI therapy resistant.
4.  Issues of the presence of Ph chromosome or BCR-ABL gene in  
non-CML hematological malignancies or healthy individuals
Ph chromosome, t(9;22)(q34.1;q11.2), was found in CML at 90–95% as men-
tioned above [41]. However, Ph chromosome has been found in other types of 
non-CML hematological malignancies.
Studies showed that acute myeloid leukemia (AML) about 3% of adult AML and 
1% in childhood have Ph chromosome [42, 43]. Different proportions of Ph chro-
mosome were found in patient with myelodysplasia syndrome (MDS) [44]. About 
20% of adult ALL and 2–5% of children have Ph chromosome in acute lymphoblas-
tic leukemia (ALL) [45–48]. The couple of T-ALL cases with positive Ph have been 
reported [49, 50]. The presence of Ph chromosome on a patient with lymphoma was 
detected by a study [51]. Positive Ph chromosome was reported from H929 multiple 
myeloma cell line [52]. Koshy group reported the presence of Ph chromosome from 
a case of pregnant women with unusual primary myelofibrosis [53].
Interestingly and surprisingly, BCR-ABL fusion gene was detected in healthy 
individuals (2/30) but without following up studies seen afterward [54]. Biernaux 
group studied the BCR-ABL gene of blood cells from healthy individuals and found 
the presence of BCR-ABL transcript (22 of 73) [55]. More evidence from a study 
of peripheral blood leukocytes conducted on 16 healthy individuals, and some cell 
lines as controls by Bose group and results showed the presence of BCR-ABL gene 
either p210 (27%) or p190 (69%) transcript in healthy individuals [56]. It is sug-
gested that leukemia-associated genes in healthy individuals require the additional 
activations to be malignancy, although no satisfactory explanation on why BCR/
ABL fusion gene detected from some healthy individuals short- and long-term 
following up.
5.  Issues of the combination of CML and chronic lymphocytic leukemia 
(CLL) in the clonal association
CML and CLL are different hematological malignancies characterized by their 
cause of disease, their origin of hematopoietic lineages, laboratory findings and 
clinical presentations, and different immune phenotypes. CML and CLL require 
different treatment strategies. In general, there are no many problems or issues in 
the diagnosis and differential diagnosis on both of CML and CLL.
Recently, there were some rare cases reported in the combination of CML and 
CLL, which raises a question as to whether the myeloid and lymphoid malignant 
clones derived from the common malignant stem cells or CML and CLL are two 
independent simultaneous events.
A group performed a study on three-way translocations by flow cytometric 
sorting using monoclonal antibody anti-CD19 lacked the BCR-ABL rearrangement. 
Their results suggested CML and CLL were from two different clones B-cell trans-
formation occurred in a Ph-B-cell subset [57].
Wu et al. reported a novel CML case with three-way translocations involved in 
chromosomes 9, 22, and 11 cytogenetically and confirmed by fluorescence in-situ 
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hybridization (FISH). It was found the deletion of chromosome short arm (4p) 
confirmed by comparative genome hybridization microarray. This patient had 
more than 10 years indolent chronic lymphoblastic leukemia (CLL) history without 
progression over several years, and cytogenetic test was normal. Interestingly, both 
CML and CLL got remission after treatment for CML indicating the possibility of 
the relevant if clonal revolution [58]. These results might indicate the association of 
Ph chromosome in the leukemogenesis of CML and CLL.
Armarego et al. reported five CML cases in the combination of CLL history and 
one case with the deletion of short arm of chromosome 17(17p). All patients were 
treated for both CLL and CML, and a satisfactory outcome was achieved from the 
five cases studied separately [59].
The association of CML and CLL raises the issues that the combination of CML 
and CLL is the two different events or a result from a clonal evolution either from 
CML or CLL that needs to be classified further.
6. Conclusion
CML is a special disease with a milestone history and remarkable nonstopping 
genetic discoveries, which have paved the path in effective treatment of CML by 
translating findings into clinical settings.
It is believed that the continuing study on genetic variations will help to develop 
TKI therapy to minimize further therapy resistance in the future.
CML is an old disease with new face. The continuous discoveries of genetic 
variations and multiway translocation of Ph chromosome in CML will help in the 
diagnosis and monitoring of treatment.
The mystery and the associations of the combination of CML and CLL in some 
reported cases are still unknown.
Such fascinating stories made the best example in the process of conquering the 
human diseases.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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